脂必泰对高脂血症患者CD40/sCD40L的调节作用

Study on Zhibitai on the serum lipid levels of sCD40L and CD40 of patients with hyperlipidemia

目的探讨脂必泰对高脂血症患者CD40/sCD40L水平的影响。方法 66例原发性高脂血症患者应用脂必泰治疗8周,分别测定治疗前(0周)、治疗4周和8周后CD40和sCD40L的浓度进行对比,同时入选44例健康者作为正常对照组。结果高脂血症组与正常对照组相比CD40/sCD40L治疗前表达明显上调,而应用脂必泰治疗4周后sCD40L即有显著下降(P<0.05);CD40治疗后亦有下降,但未达到统计学意义。结论高脂血症刺激细胞CD40/sCD40L表达显著增加,脂必泰具有抑制CD40/sCD40L信号转导通路的作用,这可能是其抗炎、抗动脉硬化的重要机制。

Objective To study the effects of Zhibitai On the serum lipid levels of sCD40L and CD40 of patients with hyperlipidemia. Methods Sixty six patients with hyperlipidemia were being treated with Zhibitai two pill bid for 8 weeks. Their blood concentrations of lipid of sCD40L were measured respectively at baseline （0 week） ,4 weeks and 8 weeks. CD40s were separated by flow cytometry at the same time. 44 normal control subjects were also investigated （just 0 week）. Results CD40/sCI）40Ls of patients were significantly increased （P 〈 0. 05 ） , however, its levels of sCD40L were fallen and there were statistical significance only after 4 weeks（ P 〈 0.05 ）. CD40 levels were not changed before and after treatment. Conclusion Hyperlipidemia stimulates upregulation the levels of CD40 and sCD40L, and Zhibitai can inhibit the CE40/sCD40L system, which may contribute to its anti -inflammatory and anti -atberogenie activity.